US Bancorp DE Lowers Stake in Boston Scientific Corp. (BSX)
US Bancorp DE lowered its stake in Boston Scientific Corp. (NYSE:BSX) by 2.2% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 456,602 shares of the company’s stock after selling 10,508 shares during the period. US Bancorp DE’s holdings in Boston Scientific Corp. were worth $10,867,000 at the end of the most recent reporting period.
A number of other large investors also recently modified their holdings of BSX. Trust Co. of Vermont increased its stake in Boston Scientific Corp. by 2,298.3% in the third quarter. Trust Co. of Vermont now owns 4,221 shares of the company’s stock worth $100,000 after buying an additional 4,045 shares during the last quarter. Synovus Financial Corp acquired a new stake in Boston Scientific Corp. during the third quarter worth $102,000. Quadrant Capital Group LLC increased its stake in Boston Scientific Corp. by 1.7% in the second quarter. Quadrant Capital Group LLC now owns 4,844 shares of the company’s stock worth $105,000 after buying an additional 83 shares during the last quarter. Global X Management Co. LLC increased its stake in Boston Scientific Corp. by 91.8% in the second quarter. Global X Management Co. LLC now owns 4,683 shares of the company’s stock worth $109,000 after buying an additional 2,242 shares during the last quarter. Finally, Gemmer Asset Management LLC increased its stake in Boston Scientific Corp. by 2.4% in the third quarter. Gemmer Asset Management LLC now owns 4,991 shares of the company’s stock worth $119,000 after buying an additional 119 shares during the last quarter. Hedge funds and other institutional investors own 89.96% of the company’s stock.
Shares of Boston Scientific Corp. (NYSE:BSX) traded down 0.87% during trading on Wednesday, hitting $20.59. 3,344,069 shares of the stock traded hands. The company has a 50 day moving average price of $22.04 and a 200 day moving average price of $23.09. Boston Scientific Corp. has a 12 month low of $15.67 and a 12 month high of $24.79. The firm has a market cap of $28.04 billion, a price-to-earnings ratio of 388.49 and a beta of 1.15.
Boston Scientific Corp. (NYSE:BSX) last posted its quarterly earnings data on Wednesday, October 26th. The company reported $0.27 earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.27. Boston Scientific Corp. had a net margin of 0.99% and a return on equity of 23.25%. The firm had revenue of $2.11 billion for the quarter, compared to analysts’ expectations of $2.07 billion. During the same quarter last year, the company posted $0.24 EPS. The business’s quarterly revenue was up 11.5% on a year-over-year basis. Analysts anticipate that Boston Scientific Corp. will post $1.10 earnings per share for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: This article was published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this article on another domain, it was illegally stolen and reposted in violation of U.S. and international copyright & trademark law. The correct version of this article can be accessed at https://www.thecerbatgem.com/2016/11/30/us-bancorp-de-lowers-stake-in-boston-scientific-corp-bsx.html.
A number of research firms have recently weighed in on BSX. TheStreet upgraded shares of Boston Scientific Corp. from a “hold” rating to a “buy” rating in a research report on Wednesday, October 26th. Zacks Investment Research downgraded shares of Boston Scientific Corp. from a “buy” rating to a “hold” rating in a research report on Monday, October 31st. Citigroup Inc. lifted their price target on shares of Boston Scientific Corp. from $28.00 to $29.00 and gave the company a “buy” rating in a research report on Thursday, October 6th. Argus upgraded shares of Boston Scientific Corp. from a “hold” rating to a “buy” rating and boosted their price objective for the company from $23.82 to $33.00 in a research report on Thursday, September 1st. They noted that the move was a valuation call. Finally, Royal Bank Of Canada restated an “outperform” rating and set a $28.00 price objective on shares of Boston Scientific Corp. in a research report on Friday, October 14th. Five research analysts have rated the stock with a hold rating and twenty-one have given a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average price target of $25.70.
About Boston Scientific Corp.
Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven core businesses: Interventional Cardiology, Peripheral Interventions (PI), Cardiac Rhythm Management (CRM), Electrophysiology (EP), Endoscopy, Urology and Pelvic Health, and Neuromodulation.
Receive News & Stock Ratings for Boston Scientific Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific Corp. and related stocks with our FREE daily email newsletter.